Skip to main content

Advertisement

Table 4 Cox proportional regression analysis of the associations between patient characteristics and OS in all 6031 NPC patients

From: A new prognostic histopathologic classification of nasopharyngeal carcinoma

Characteristic Patients [cases (%)] OS rate (%) Unadjusted HR 95% CI P value Adjusted HRa 95% CI P value
5-year 95% CI
Proposed classification
 EC 3708 (61.5) 79.4 78.1–80.8 1.00 Reference   1.00 Reference  
 MSEC 1247 (20.7) 70.5 67.7–73.0 1.48 1.32–1.67 <0.001 1.44 1.27–1.62 <0.001
 SC 823 (13.6) 59.6 55.9–63.1 2.16 1.90–2.44 <0.001 2.00 1.76–2.28 <0.001
 SCC 253 (4.2) 42.6 35.8–49.3 3.56 2.96–4.28 <0.001 4.23 3.34–5.38 <0.001
Age
 ≤47 years 3163 (52.5) 77.8 76.3–79.3 1.00 Reference   1.00 Reference  
 >47 years 2868 (47.5) 68.4 66.6–70.2 1.54 1.40–1.70 <0.001 1.50 1.36–1.65 <0.001
Sex
 Male 4468 (74.1) 71.7 70.3–73.1 1.00 Reference   1.00 Reference  
 Female 1563 (25.9) 78.1 75.8–80.2 0.73 0.65–0.81 <0.001 0.76 0.68–0.86 <0.001
Therapeutic modality
 Radiotherapy alone 2739 (45.4) 71.4 69.6–73.1 1.00 Reference   1.00 Reference  
 Radiochemotherapy 3292 (54.6) 75.2 73.4–76.8 0.88 0.79–0.97 0.009 0.65 0.59–0.72 <0.001
Clinical stage
 I 177 (2.9) 92.4 87.1–95.5 1.00 Reference   1.00 Reference  
 II 1041 (17.3) 85.6 83.2–87.6 2.20 1.27–3.79 0.004 2.25 1.3–3.89 0.003
 III 2424 (40.2) 74.3 72.4–76.0 4.17 2.46–7.08 <0.001 4.70 2.76–7.98 <0.001
 IV 2389 (39.6) 64.9 62.7–67.0 5.77 3.40–9.78 <0.001 6.96 4.09–11.85 <0.001
WHO classification
 NKUC 4871 (80.8) 73.8 72.5–75.1 1.00 Reference   1.00 Reference  
 NKDC 1050 (17.4) 73.2 70.1–75.9 1.02 0.90–1.16 0.729 1.00 0.87–1.16 0.980
 KSCC 110 (1.8) 57.5 47.0–66.6 1.85 1.38–2.47 <0.001 0.51 0.35–0.74 <0.001
  1. OS overall survival, NPC nasopharyngeal carcinoma, HR hazard ratio, CI confidence interval, EC epithelial carcinoma, MSEC mixed sarcomatoid-epithelial carcinoma, SC sarcomatoid carcinoma, SCC squamous cell carcinoma, WHO World Health Organization, NKUC non-keratinizing undifferentiated carcinoma, NKDC non-keratinizing differentiated carcinoma, KSCC keratinizing squamous cell carcinoma
  2. a All models were adjusted for the proposed classification, age, sex, therapeutic modality, clinical stage, and WHO classification